Valeant gets extra month from lenders to file annual report

Canadian pharma company says it remains well positioned to meet its obligations

Shake-up at Valeant signals stunning fall from grace for J Michael Pearson

Pharmaceutical giant faces a growing list of questions from investors and regulators

Stocktake: Stocks propped up by buybacks binge

Valeant says chief executive Michael Pearson to step down

Company has appointed activist investor William Ackman to its board

Valeant Pharmaceuticals International cuts revenue forecast

The Canadian drugmaker cut its 2016 forecast by about 12% causing shares to plunge

Valeant insists key executive resigned and was not asked to go

Deb Jorn oversaw the Canadian pharmaceutical’s US dermatology business

Valeant shares slump on new SEC investigation

News comes as Canadian drug-maker pulled 2016 forecasts

Drugmaker Valeant pulls forecasts as Pearson returns

Chief executive back at the helm after two-month absence through illness but Robert Ingram retains chairman’s post

Shares in Canadian drugmaker Valeant decline steeply for second day running

Wall Street Journal reports that pharmaceutical firm plans to restate earnings

Ackman hedge fund sells down part of Valeant stake

Pershing Square Capital increased stake in beleaguered drug group last November but acts to generate tax loss for investors

Joe Nocera: Valeant Pharmaceuticals looking like another Enron

Eye-popping growth and questionable acquisitions raise far too many questions

Valeant raises forecasts after topping expectations in first quarter

Fast-growing company loses CFO Howard Schiller as it looks to address issues with $11bn Salix Pharma acquisition

Botox maker Allergan in $66bn deal with Actavis

Allergan employs about 900 here, most at its manufacturing plant in Westport

Valeant to raise Allergan bid to at least $200 a share

Pharmaceutical firm’s offer values the Botox maker at $53bn